Table 3.

Threshold Analyses

HGD	Strategy Change
Residual HGD after Ablation	Assume No Complete Ablation of Metaplasia
RFA: ≤ 0.17	RFA Cost-Effective
RFA: > 0.17	APC Cost-Effective (WTP $100,000)
RFA: > 0.18	APC Cost-Effective (WTP $50,000)
RFA/APC: > 0.23	PDT Cost-Effective (WTP $100,000)
RFA/APC: > 0.30	PDT Cost-Effective (WTP $50,000)
RFA/APC/PDT: > 0.75	Surveillance Cost-effective (WTP $100,000)
Cost of Ablation
RFA: ≤ $8,500	RFA Cost-Effective
RFA: > $9,000	APC Cost-Effective (WTP $100,000)
RFA: > $11,000	APC Cost-Effective (WTP $50,000)
RFA/APC: > $17,500	PDT Cost-Effective (WTP $100,000)
RFA/APC: > $18,500	PDT Cost-Effective (WTP $50,000)
LGD
Residual LGD after Ablation+	Assume No Complete Ablation of Metaplasia
< 54%	Ablation Cost-Effective (WTP $50,000)
< 72%	Ablation Cost-Effective (WTP $100,000)
≥72%	Surveillance Cost-Effective
Cost of Ablation+
≤$15,000	Ablation Cost-Effective (WTP $50,000)
< $26,000	Ablation Cost-Effective (WTP $100,000)
≥$26,000	Surveillance Cost-Effective
Cost of EGD+
No threshold identified	Ablation Cost-Effective or Dominant
Perforation or Stricture with Ablation+
No threshold identified	Ablation Cost-Effective or Dominant
No Dysplasia
Complete Ablation of Metaplasia+
≤40%	Surveillance Cost-Effective
> 40%	Ablation Without Surveillance Cost-Effective (WTP $100,000)
> 47%	Ablation Without Surveillance Cost-Effective (WTP $50,000)
Ablation without surveillance always preferred over ablation with surveillance
Cost of Ablation+
No threshold identified	Ablation without surveillance cost-effective

HGD: high-grade dysplasia; LGD: low-grade dysplasia; RFA: radiofrequency ablation; APC: argon plasma coagulation; PDT: photodynamic therapy; EGD: esophagogastroduodenoscopy; WTP: willingness to pay

⁺Ablation based on RFA parameter estimates